TMPRSS2 and prostate carcinoma: Notably, the TMPRSS2-ERG fusion, which is present in approximately 50% of prostate cancers, leads to an AR-mediated upregulation of ERG signaling and is implicated in pathways that lead to metastasis rather than cell growth [37].